10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2007

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to            .

Commission File Number  001-32374

SYMMETRY MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware	35-1996126
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

220 W. Market Street, Warsaw, Indiana	46580
(Address of principal executive offices)	(Zip code)

Registrants telephone number, including area code  (574) 268-2252

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  x   No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check One)

Large accelerated filer  o Accelerated filer  x Non-accelerated filer  o

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).   Yes  o   No  x

The number of shares outstanding of the registrant’s common stock as of April 10, 2007 was 35,293,651.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION
Item 1     -	Financial Statements:
	Condensed Consolidated Balance Sheets: As of March 31, 2007 and December 30, 2006
	Condensed Consolidated Statements of Operations: Three Months Ended March 31, 2007 and April 1, 2006
	Condensed Consolidated Statements of Cash Flows: Three Months Ended March 31, 2007 and April 1, 2006
	Notes to Condensed Consolidated Financial Statements
Item 2	Management’s Discussion and Analysis of Results of Operations and Financial Condition
Item 3	Quantitative and Qualitative Disclosures about Market Risks
Item 4	Controls and Procedures
PART II OTHER INFORMATION
Item 1	Legal Proceedings
Item 1A	Risk Factors
Item 2	Unregistered Sale of Equity Securities and Use of Proceeds
Item 5	Other Information
Item 6	Exhibits
Signatures

2

Symmetry Medical Inc.
Condensed Consolidated Balance Sheets

	March 31,		December 30,
	2007		2006
	(In Thousands, Except Per Share Data)
	(unaudited)
Assets:
Current Assets:
Cash and cash equivalents	$	6,094	$	11,721
Accounts receivables, net	55,267		47,506
Inventories	49,253		47,392
Refundable income taxes	112		111
Deferred income taxes	3,534		2,826
Other current assets	3,820		3,965
Total current assets	118,080		113,521
Property and equipment, net	109,413		106,147
Goodwill	157,885		156,241
Intangible assets, net of accumulated amortization	36,830		33,257
Other assets	922		981
Total Assets	$	423,130	$	410,147
Liabilities and Shareholders' Equity:
Current Liabilities:
Accounts payable	$	19,170	$	14,860
Accrued wages and benefits	10,168		7,816
Other accrued expenses	4,723		4,104
Income tax payable	1,281		850
Deferred income taxes	337		249
Derivative valuation liability	546		1,184
Revolving line of credit	2,215		—
Current portion of capital lease obligations	2,956		3,500
Current portion of long-term debt	7,837		5,550
Total current liabilities	49,233		38,113
Deferred income taxes	11,662		11,832
Derivative valuation liability	893		549
Capital lease obligations, less current portion	5,400		5,142
Long-term debt, less current portion	59,110		63,650
Total Liabilities	126,298		119,286
Commitments and contingencies (Note 8)	—		—
Shareholders' Equity:
Common Stock, $.0001 par value; 72,410 shares authorized; shares issued March 31, 2007--35,294; December 30, 2006--35,107)	4		4
Additional paid-in capital	272,977		271,388
Retained earnings	10,481		6,771
Accumulated other comprehensive income	13,370		12,698
Total Shareholders' Equity	296,832		290,861
Total Liabilities and Shareholders' Equity	$	423,130	$	410,147

See accompanying notes to condensed consolidated financial statements.

3

Symmetry Medical Inc.
Condensed Consolidated Statements of Operations

	Three Months Ended
	March 31,			April 1,
	2007			2006
	(In Thousands, Except Per Share Data)
	(unaudited)			(unaudited)
Revenue	$	67,519		$	69,613
Cost of Revenue	52,558			49,272
Gross Profit	14,961			20,341
Selling, general, and administrative expenses	7,873			7,040
Operating Income	7,088			13,301
Other (income) expense:
Interest expense	1,587			661
Derivatives valuation (gain)/loss	(295		)	(1		)
Other	546			(219		)
Income before income taxes	5,250			12,860
Income tax expense	1,540			4,483
Net income	$	3,710		$	8,377
Net income per share:
Basic	$	0.11		$	0.24
Diluted	$	0.11		$	0.24
Weighted average common shares and equivalent shares outstanding:
Basic	34,973			34,717
Diluted	35,194			35,137

See accompanying notes to condensed consolidated financial statements.

4

Symmetry Medical Inc.
Condensed Consolidated Statements of Cash Flows

	Three Months Ended
	March 31,			April 1,
	2007			2006
	(In Thousands)
	(unaudited)			(unaudited)
Operating activities
Net Income	$	3,710		$	8,377
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	4,179			3,704
Amortization	494			151
Foreign currency transaction (gain) loss	(11		)	(284		)
Net loss on sale of assets	2			13
Deferred income tax provision	(890		)	(233		)
Excess tax benefit from stock-based compensation	(796		)	(1,062		)
Stock-based compensation	244			108
Derivative valuation change	(295		)	(1		)
Change in operating assets and liabilities:
Accounts receivable	(5,462		)	(4,406		)
Other assets	190			108
Inventories	(175		)	(620		)
Accounts payable	3,591			(4,109		)
Accrued expenses and other	2,976			981
Net cash provided by operating activities	7,757			2,727
Investing activities
Purchases of property and equipment	(3,473		)	(5,085		)
Proceeds from the sale of fixed assets	28			—
Acquisition, net of cash received	(10,317		)	—
Net cash used in investing activities	(13,762		)	(5,085		)
Financing activities
Proceeds from bank revolver	16,473			4,641
Payments on bank revolver	(16,502		)	(3,028		)
Payments on long-term debt and capital lease obligations	(903		)	(2,384		)
Proceeds from the issuance of common stock, net of expenses	549			404
Excess tax benefit from stock-based compensation	796			1,062
Net cash provided by financing activities	413			695
Effect of exchange rate changes on cash	(35		)	108
Net increase (decrease) in cash and cash equivalents	(5,627		)	(1,555		)
Cash and cash equivalents at beginning of period	11,721			12,471
Cash and cash equivalents at end of period	$	6,094		$	10,916
Supplemental disclosures:
Cash paid for interest	$	1,606		$	512
Cash paid for income taxes	$	1,449		$	2,034

See accompanying notes to condensed consolidated financial statements.

5

Symmetry Medical Inc.
Notes to Condensed Consolidated Financial Statements
(In Thousands, Except Per Share Data)

1. Basis of Presentation

The condensed consolidated financial statements include the accounts of Symmetry Medical, Inc. and its wholly-owned subsidiaries (collectively referred to as the Corporation), Symmetry Medical USA Inc., Jet Engineering, Inc., Ultrexx, Inc., Riley Medical Inc., Symmetry Medical Switzerland SA, Symmetry Medical Everest LLC, Everest Metal International Limited, Symmetry Medical Cheltenham Limited, Symmetry Medical PolyVac, SAS, Thornton Precision Components Limited, Symmetry Medical Malaysia SDN and Clamonta Limited.  The Corporation is a global supplier of integrated products and services consisting primarily of surgical implants, instruments and cases to orthopedic and other medical device companies.

The condensed consolidated financial statements of the Corporation have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all material adjustments (consisting only of normal recurring adjustments) necessary to present fairly the consolidated financial position of the Corporation, its results of operations and cash flows. The Corporation’s results are subject to seasonal fluctuations. Interim results are not necessarily indicative of results for a full year. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in the Corporation’s Annual Report on Form 10-K for fiscal year 2006.

Certain prior year amounts have been reclassified to conform to the current-year presentation. These reclassifications had no impact on our results of operations or financial position.

The Corporation’s year end is the 52 or 53 week period ending the Saturday closest to December 31. Fiscal year 2007 and 2006 are 52 week years. As such, interim quarters are 13 weeks long ending the Saturday closest to March 31, June 30, or September 30. References in these consolidated financial statements to the three months ended refer to these financial periods, respectively.

Riley Medical Inc. and Symmetry Medical Switzerland SA were acquired on May 2, 2006 and are collectively referred to as “Riley Medical.”  Symmetry Medical Everest LLC and Everest Metal International Limited were acquired on August 31, 2006 and are collectively referred to as “Everest Metal.”  The Corporation’s Annual Report on Form 10-K for fiscal year 2006 contains additional information on these acquisitions.

On January 9, 2007, the Corporation’s subsidiary Thornton Precision Components Limited (Thornton) acquired all of the stock of Whedon Limited, a privately owned company based in Warwickshire, UK and the holding company of Clamonta Limited (collectively “Clamonta Ltd”), for $10,317 in cash, subject to certain post closing adjustments.  Clamonta Ltd manufactures aerospace products for the global aerospace industry.

2. Inventories

Inventories consist of the following:

	March 31,		December 30,
	2007		2006
Raw material and supplies	$	8,234	$	10,661
Work-in-process	30,256		25,076
Finished goods	10,763		11,655
	$	49,253	$	47,392

3. Property and Equipment

Property and equipment, including depreciable lives, consists of the following:

6

	March 31,			December 30,
	2007			2006
Land	$	2,321		$	1,531
Buildings and improvements (20 to 40 years)	30,823			29,957
Machinery and equipment (5 to 15 years)	126,588			121,457
Office equipment (3 to 5 years)	6,911			6,832
Construction-in-progress	5,253			4,800
	171,896			164,577
Less accumulated depreciation	(62,483		)	(58,430		)
	$	109,413		$	106,147

4. Intangible Assets

Intangible assets acquired in connection with our acquisitions of Mettis (UK) Limited, Riley Medical, Everest Metal and Clamonta Ltd.

As of March 31, 2007, the balances of intangible assets, other than goodwill, were as follows:

	Weighted-average	Gross					Net
	Amortization	Intangible		Accumulated			Intangible
	Period	Assets		Amortization			Assets
Acquired technology and patents	12 years	$	1,575	$	(413	)	$	1,162
Acquired customers	19 years	31,525		(2,875		)	28,650
Non-compete agreements	5 years	402		(47		)	355
Intangible assets subject to amortization		33,502		(3,335		)	30,167
Proprietary processes	Indefinite						3,892
Trademarks	Indefinite						2,771
Indefinite-lived intangible assets, other than goodwill							6,663
Total							$	36,830

5. New Accounting Pronouncements

Accounting for Uncertainty in Income Taxes

The Corporation adopted the provisions of FASB Interpretation No. 48 (“FIN 48”), Accounting for Uncertainty in Income Taxes, on December 31, 2006.  The implementation of FIN 48 had no impact on the Corporation’s financial position or results of operations.  As of the beginning of fiscal year 2007, the Corporation had unrecognized tax benefits of $339.  There has been no significant change in the unrecognized tax benefits during the first quarter ending March 31, 2007

The Corporation recognizes interest and penalties related to unrecognized tax benefits through income tax expense.  The Corporation has not accrued any interest or penalties as of March 31, 2007. 

The Corporation is subject to periodic audits by domestic and foreign tax authorities.  Currently, the Corporation is undergoing routine periodic audits in both domestic and foreign tax jurisdictions.  It is reasonably possible that the amounts of unrecognized tax benefits could change in the next 12 months as a result of the audits.  It is impossible to estimate the significance of such a potential change at this time.  For the majority of tax jurisdictions, the Corporation is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for fiscal years before 2003.

The Fair Value Option for Financial Assets and Financial Liabilities

In February 2007, the FASB issued Statement of Financial Accounting Standard (SFAS) No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. This Statement permits entities to choose to measure many financial instruments and certain other instruments at fair value. This Statement is effective for fiscal years beginning after November 15, 2007. The adoption of this Statement is not expected to have a material impact on the Corporation’s financial position, results of operations or cash flows.

6. Segment Reporting

The Corporation primarily designs, develops and manufactures implants and related surgical instruments and cases for orthopedic device companies and companies in other medical device markets such as dental, osteobiologic and endoscopy. The Corporation also has a special services business serving primarily aerospace customers, which does not meet the quantitative disclosure requirements of SFAS 131. The Corporation manages its business in multiple operating segments. Because of the similar economic characteristics of the operations, including the nature of the products, comparable level of FDA regulations, same or similar customers, those operations have been aggregated following the provisions of SFAS 131 for segment reporting purposes.

7

The Corporation is a multi-national corporation with operations in the United States, the United Kingdom, Ireland, Switzerland, France and Malaysia. As a result, the Corporation’s financial results can be impacted by currency exchange rates in the foreign markets in which the Corporation sells its products. While exposure to variability in foreign currency exists, the Corporation does not believe it is significant to its operations and any variability is somewhat offset through the location of its manufacturing facilities. Revenue is attributed to geographic locations based on the location to which we ship our products.

Revenue from External Customers:

	Three Months Ended
	March 31,		April 1,
	2007		2006
United States	$	39,359	$	46,347
United Kingdom	13,743		7,728
Ireland	6,569		9,525
Other foreign countries	7,848		6,013
Total net revenues	$	67,519	$	69,613

Concentration of Credit Risk:

A substantial portion of the Corporation’s revenue is derived from a limited number of customers. The Corporation’s revenue includes revenue from customers of the Corporation which individually account for 10% or more of revenue as follows:

Quarter ended March 31, 2007—Four customers representing approximately 17%, 12%, 11% and 11% of revenue, respectively.

Quarter ended April 1, 2006—Two customers representing approximately 30% and 17% of revenue, respectively.

Following is a summary of the composition by product category of the Corporation’s revenue to external customers. Revenue of the specialty services business is included in the “other” category.

	Three Months Ended
	March 31,		April 1,
	2007		2006
Implants	$	24,486	$	26,591
Instruments	15,243		21,578
Cases	17,586		14,671
Other	10,204		6,773
Total net revenues	$	67,519	$	69,613

7. Net Income Per Share

The following table sets forth the computation of earnings per share.

8

	Three Months Ended
	March 31,		April 1,
	2007		2006
Net income	$	3,710	$	8,377
Weighted-average common shares outstanding basic	34,973		34,717
Effect of stock options, restricted stock and stock warrants	221		420
Weighted-average common shares outstanding and assumed conversions	35,194		35,137
Net income per share:
Basic	$	0.11	$	0.24
Diluted	$	0.11	$	0.24

During the three month period ended March 31, 2007, the Corporation issued 178 shares of common stock through the exercise of stock options.

8. Commitments and Contingencies

The Corporation is involved, from time to time, in various contractual, product liability, patent (or intellectual property) and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Corporation, threatened, that the Corporation expects to have a material adverse affect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Corporation currently believes that the disposition of all pending or, to the knowledge of the Corporation threatened, claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Corporation’s consolidated financial condition, results of operations or liquidity.

9. Comprehensive Income

Comprehensive income is comprised of net income and gains and losses resulting from currency translations of foreign entities. Comprehensive income consists of the following:

	Three Months Ended
	March 31,		April 1,
	2007		2006
Net Income	$	3,710	$	8,377
Foreign currency translation adjustments	672		942
Comprehensive income	$	4,382	$	9,319

10. Acquisitions

On January 9, 2007, the Corporation’s subsidiary Thornton Precision Components Limited (Thornton) acquired all of the stock of Whedon Limited, a privately owned company based in Warwickshire, UK and the holding company of Clamonta Limited (collectively “Clamonta Ltd”), for $10,317 in cash, subject to certain post closing adjustments.  The acquisition of Clamonta Ltd expands the Corporation’s Total Solutions ® business model into the global aerospace industry and further strengthens our relationship with a key aerospace customer.  Results of Clamonta Ltd are included from the date of acquisition.

The aggregate purchase price is preliminary, subject to adjustment and expected to be finalized in the third fiscal quarter. As of March 31, 2007, the aggregate purchase price of $10,317 was allocated to the opening balance sheet as follows:

9

Current assets	$	3,596
PP&E	3,695
Acquired customers (amortized over 15 years)	2,430
Non-compete agreements (amortized over 5 years)	110
Trademarks (indefinite-lived)	1,450
Goodwill	1,397
Current liabilities	(1,811		)
Capital Leases	(550		)
Purchase price, net	$	10,317

Pro forma results for Clamonta Ltd have not been presented as the impacts of Clamonta Ltd to the first quarter are not material.

On August 31, 2006, the Corporation completed the acquisition of Everest Metal for approximately $9,214 in net cash, subject to adjustment and an earn-out provision.  The earn-out provision requires payments of up to approximately $1,081 after the end of 2007 if certain revenue targets are met.

11. Subsequent Event

Symmetry Medical USA Inc., a wholly owned subsidiary of Symmetry Medical Inc. (“Symmetry Medical”), entered into a definitive stock purchase agreement on April 2, 2007 and subsequently closed on April 3, 2007 on the purchase of all the issued and outstanding stock of TNCO, Inc. (“TNCO”), a privately owned company based in Whitman, Massachusetts. The cash purchase price was $7,000, subject to certain post closing adjustments. TNCO designs and supplies precision instruments for arthoscopic, laparoscopic, sinus, and other minimally invasive procedures.

10

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Overview

We are a leading independent provider of implants and related instruments and cases to orthopedic device manufacturers and other medical markets. We also design, develop and produce these products for companies in other segments of the medical device market, including dental, osteobiologic and endoscopy sectors, and provide limited specialized products and services to non-healthcare markets, primarily the aerospace industry.

We offer our customers Total Solution® for complete implant systems—implants, instruments and cases. While our revenue to date has been derived primarily from the sale of implants, instruments and cases separately, or instruments and cases together, our ability to provide Total Solutions® for complete implant systems has already proven to be attractive to our customers, and we expect this capability will provide us with growth opportunities. In addition, we expect that our Total Solutions® capability will increase the relative percentage of value added products that we supply to our customers.

Our Annual Report on Form 10-K for the fiscal year ended December 30, 2006, provides additional information about our business, operations and financial condition.

During the first quarter 2007, our revenue growth of 15.5% over the fourth quarter of 2006 was driven by a slow ramp-up in our core orthopedics business and continued momentum from the integration of our acquisitions.  Revenue decreased 3.0% in the first quarter 2007 compared to 2006 as revenue from our top five orthopedic customers was down 24% and represented 58% of total revenues.  Quarterly revenue from all other customers increased 47% compared to the same period last year.  Our long-term strategy is to diversify our customer base and expand into other medical device markets outside of our core hip and knee business.  While we continue to make progress on these initiatives, it did not fully offset the reduced demand from our top five customers.

A significant part of our business strategy has been growth through acquisitions which have enhanced our product offerings and our business model.  We acquired Riley Medical Inc. and Symmetry Medical Switzerland SA (collectively “Riley Medical”) on May 2, 2006 for $45.8 million.  Riley Medical is a leading designer and manufacturer of specialty cases and trays for the global medical market.  We also acquired Symmetry Medical Everest LLC and Everest Metal International Limited (collectively “Everest Metal”) on August 31, 2006 for $9.2 million.  Everest Metal specializes in implant finishing.  On January 9, 2007, our wholly-owned subsidiary Thornton Precision Components Limited (Thornton) acquired all of the stock of Whedon Limited, a privately owned company based in Warwickshire, UK and the holding company of Clamonta Limited (collectively “Clamonta Ltd”), for $10.3 million in cash, subject to certain post closing adjustments.  Clamonta Ltd machines high-precision specialty parts for the global aerospace industry.

Subsequent to the quarter end, our wholly-owned subsidiary, Symmetry Medical USA Inc. entered into a definitive stock purchase agreement on April 2, 2007 and subsequently closed on April 3, 2007 on the purchase of all the issued and outstanding stock of TNCO, Inc. (“TNCO”), a privately owned company based in Whitman, Massachusetts. The cash purchase price was $7.0 million, subject to certain post closing adjustments. TNCO designs and supplies precision instruments for arthoscopic, laparoscopic, sinus, and other minimally invasive procedures.

While acquisitions are an important part of our growth strategy and we have a strong pipeline across several diverse medical device segments, we continue to invest in our core business with the ramp-up of our Malaysian facility, the introduction of new Symmetry products and innovation with new materials and technologies, such as carbon fiber, to our product offerings.  On April 30, 2007, we announced the introduction of a new proprietary printing technology for our cases, DigiPrint, that will allow us to employ a non-toxic, durable graphics printed below the surface of the metal making it impervious to scratching, peeling and fading.

Our focus remains on being well positioned for a resurgence of growth in our core orthopedic business, while capitalizing on our market leadership to extend our Total Solutions® approach into other markets.  In particular, we continue to expand our engineering resources that produce and provide closer and critical customer relationships on the development of new products.  This local presence in the global marketplace allows us to be closer to our customer base, provide quicker response times and increase our value added services.

First Quarter Results of Operations

Revenue.   Revenue for the period ended March 31, 2007 decreased $2.1 million, or 3.0%, to $67.5 million from $69.6 million for the comparable 2006 period.  Revenue for each of our principal product categories in these periods was as follows:

11

Product Category	Three Months Ended
	March 31,		April 1,
	2007		2006
	(in millions)
Implants	$	24.5	$	26.6
Instruments	15.2		21.5
Cases	17.6		14.7
Other	10.2		6.8
Total	$	67.5	$	69.6

The $2.1 million reduction in revenue resulted from lower implant and instrument revenue of $2.1 million and $6.3 million, respectively.  Implant revenues included $2.0 million from our Everest metal acquisition.  These reductions were partially offset by increased case revenue of $2.9 million, including $6.2 million of revenue from the Riley Medical acquisition.  Overall, implant, instrument and case revenue from our top five customers was down 24% as we faced a challenging quarterly comparison due to the completion of several projects for our largest customers in the first quarter of 2006.  Other increased $3.4 million driven by the continued strength in the aerospace industry and included $2.9 million from the Clamonta Ltd acquisition in the first quarter of 2007.

Gross Profit.  Gross profit for the three month period ended March 31, 2007 decreased $5.4 million, or 26.4%, to $15.0 million from $20.3 million for the comparable 2006 period.  The decrease in gross profit was driven by the 3.0% decrease in revenue coupled with lower gross profit as a percentage of revenue which declined to 22.2% for the three month period ended March 31, 2007 compared to 29.2% for the comparable 2006 period.  The decline in gross margin as a percentage of revenue was primarily driven by fewer large volume projects from our top five customers which resulted in increased overhead costs as a percentage of revenue as well as less favorable product mix.  We view our global infrastructure as a competitive strength, and we have made a deliberate decision to keep our infrastructure in place, enabling us to respond quickly to our customers’ needs and produce high volume orders on short notice.

Selling, General and Administrative Expenses.  Selling, general and administrative expenses for the three month period ended March 31, 2007 increased $0.8 million, or 11.8%, to $7.9 million from $7.0 million for the comparable 2006 period.  Additional costs related to Riley Medical, Everest metal and Clamonta Ltd accounted for $1.1 million of the increase which included $0.3 million of additional intangible asset amortization.  As a percentage of revenue, selling, general and administrative expenses increased to 11.7% of revenue for the three month period ended March 31, 2007 from 10.1% of revenue for the comparable 2006 period primarily due to the reduction in revenue.

Other Expense.   Interest expense for the three month period ended March 31, 2007 increased $0.9 million, or 140.1%, to $1.6 million from $0.6 million for the comparable 2006 period. This increase reflects the additional $40.0 million senior term debt related to the acquisition of Riley Medical.  This increase was partially offset by the reduction in outstanding capital lease obligations and existing senior term debt through normal amortization.  No additional borrowings were needed to complete the Everest Metal acquisition; however, approximately $5 million in revolving senior term debt was initially drawn to facilitate the Clamonta Ltd acquisition.

The derivatives valuation (gains) losses consist of interest rate swap valuations used to mitigate the effect of changing interest rates on net income and foreign currency forward contracts used to mitigate the effect of changes in the foreign exchange rates on net income. The increase in the gain of $0.3 million for the three month period ended March 31, 2007 versus the comparable 2006 period is due to market fluctuations in these contracts, which are not designated as hedges under SFAS 133. During the first quarter of 2007, we settled one of our foreign exchange rate contracts at a loss of $0.6 million.  Realized losses are included in the Other expense category.  No contracts were settled in the first quarter of 2006.

Provision for Income Taxes.   Our effective tax rate was 29.3% for the three month period ended March 31, 2007 as compared to 34.9% for the comparable 2006 period. Provision for income taxes decreased by $2.9 million, or 65.6%, to $1.5 million for the three month period ended March 31, 2007 from $4.5 million for the comparable 2006 period. This decrease in rate was primarily due to a higher percentage of income coming from lower tax jurisdictions outside of the United States and increased research and development tax credits and Indiana development tax credits in the current period.  We did not record a Federal research and development tax credit in the first quarter of 2006 since the United States government had not yet reinstated Section 41 of the U.S. tax code.

Liquidity and Capital Resources

Our principal sources of cash in the three month period ended March 31, 2007 were cash generated from operations, borrowings under our senior credit revolving loan facility and U.K. revolving credit facility and proceeds from the exercise of common stock options.  Principal uses of cash in the three month period ended March 31, 2007 included capital expenditures, the acquisition of Clamonta Ltd and debt service. We expect that our principal uses of cash in the future will be to finance working capital, to pay for capital expenditures, to service debt and to fund mergers and acquisitions.

We completed the acquisition of Clamonta Ltd on January 9, 2007 for $10.3 million, subject to adjustment, through the use of the existing cash balances and our $40.0 million senior debt facility.   On April 3, 2007, we completed the acquisition of

12

TNCO for approximately $7.0 million, subject to adjustment, through the use of existing cash balances and our $40.0 million senior debt facility.

Operating Activities   We generated cash from operations of $7.8 million in the three month period ended March 31, 2007 compared to $2.7 million for the three month period ended April 1, 2006 an increase of $5.1 million.  The increase in cash from operations is primarily a result of cash provided by working capital, offset by a decrease in net income of $4.7 million.

Cash provided by working capital fluctuations was $1.1 million in the three month period ended March 31, 2007 as compared to a use of $8.0 million in the comparable 2006 period.  The primary uses of cash for working capital came from an increase in accounts receivable of $5.5 million.  Primary sources of cash due to changes in working capital were increases in accounts payable and accrued expenses of $6.6 million.  Increases in accounts receivable, accounts payable and accrued expenses are a result of increasing production activity in the first quarter of 2007 compared to decreasing production activity in the first quarter of 2006.

Investing Activities  Capital expenditures of $3.5 million were lower by $1.6 million, or 31.7%, in the three month period ended March 31, 2007 compared to the three month period ended April 1, 2006.  The acquisition of Clamonta Ltd used $10.3 million of cash in the 2007 period with no comparable acquisition activity in the 2006 period.

Financing Activities   Financing activities generated $0.4 million of cash due primarily to the exercise of stock options offset by payments on long-term debt and capital leases.

Capital Expenditures

Capital expenditures totaled $3.5 million for the three months ended March 31, 2007, compared to $5.1 million for the three month period ended April 1, 2006. Expenditures were primarily used to complete our Sheffield, U.K. facility for increased forge and machining capacity for the aerospace products, and maintain production capacity in all of our production facilities.

Debt and Credit Facilities

As of March 31, 2007, we had an aggregate of $77.5 million of outstanding indebtedness, which consisted of $64.2 million of term loan borrowings outstanding under our senior credit facility, $2.7 million of borrowings outstanding under our revolving credit facility, $2.2 million of borrowings under our U.K. short-term credit facility and $8.4 million of capital lease obligations. We had no outstanding letters of credit as of March 31, 2007.

Our senior credit agreement contains various financial covenants, including covenants requiring a maximum total debt to EBITDA ratio, minimum EBITDA to interest ratio and a minimum EBITDA to fixed charges ratio. We were in compliance with our financial and restrictive covenants under the senior credit facility as of March 31, 2007.

We believe that cash flow from operating activities and borrowings under our senior credit facility will be sufficient to fund currently anticipated working capital, planned capital spending, debt service requirements for the foreseeable future, including at least the next twelve months. We also review technology, manufacturing and other strategic acquisition opportunities regularly, which may require additional debt or equity financing.

Contractual Obligations and Commercial Commitments

There have been no material changes from the information provided in our Annual Report on Form 10-K for fiscal year ended December 30, 2006.

Off-Balance Sheet Arrangements

Our off-balance sheet arrangements and contractual obligations include our operating leases and letters of credit. There have been no material changes from the information provided in our Annual Report on Form 10-K for fiscal year ended December 30, 2006.

Environmental

There have been no material changes from the information provided in our Annual Report on Form 10-K for fiscal year ended December 30, 2006.

Critical Accounting Policies and Estimates

The preparation of our financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. Our Annual Report on Form 10-K for fiscal year ended December 30, 2006 includes a summary of the critical accounting policies we believe are the most important to aid in understanding its financial results. There have been no material changes to these critical accounting policies that impacted our reported amounts of assets, liabilities, revenues or expenses during the three months ended March 31, 2007.

New Accounting Pronouncements

Accounting for Uncertainty in Income Taxes

The Corporation adopted the provisions of FASB Interpretation No. 48 (“FIN 48”), Accounting for Uncertainty in Income

13

Taxes, on December 31, 2006.  The implementation of FIN 48 did not have an impact on the Corporation’s financial position or results of operations.  As of the beginning of fiscal year 2007, the Corporation had unrecognized tax benefits of $339.  There has been no significant change in the unrecognized tax benefits during the first quarter ending March 31, 2007.

The Corporation recognizes interest and penalties related to unrecognized tax benefits through income tax expense.  The Corporation has not accrued any interest or penalties as of March 31, 2007. 

The Corporation is subject to periodic audits by domestic and foreign tax authorities.  Currently, the Corporation is undergoing routine periodic audits in both domestic and foreign tax jurisdictions.  It is reasonably possible that the amounts of unrecognized tax benefits could change in the next 12 months as a result of the audits.  It is not possible to estimate the significance of such a potential change at this time.  For the majority of tax jurisdictions, the Corporation is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for fiscal years before 2003.

The Fair Value Option for Financial Assets and Financial Liabilities

In February 2007, the FASB issued Statement of Financial Accounting Standard (SFAS) No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. This Statement permits entities to choose to measure many financial instruments and certain other instruments at fair value. This Statement is effective for fiscal years beginning after November 15, 2007. The adoption of this Statement is not expected to have a material impact on the Corporation’s financial position, results of operations or cash flows.

Cautionary Notice Regarding Forward-Looking Statements

Certain statements contained in this Quarterly Report on Form 10-Q and other written and oral statements made from time to time by the Corporation do not relate strictly to historical or current facts. As such they are considered “forward-looking statements” that provide current expectations or forecasts of future events. Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “could,” “estimate,” “intend” and similar words, although some forward-looking statements are expressed differently. Factors that could cause the Corporation’s actual results to differ materially from the expectations expressed in our forward-looking statements include, but are not limited to, the following: changes in general economic conditions in the United States and Europe; our ability to retain existing customers, particularly our key customers, and attract new customers; the timing of significant orders and shipments, including the effects of changes in inventory management practices by our customers; the competitive nature of the orthopedic device market; the pursuit of strategic acquisitions or encountering unforeseen difficulties in integrating acquisitions; the degree to which we are leveraged and our significant debt service obligations; the impact of work stoppages and other labor matters; general economic or business conditions affecting the orthopedic device market being less favorable than expected; our ability to anticipate changes in technology and regulatory standards and to successfully develop and introduce new and enhanced products on a timely basis; the unpredictability of intellectual property protection and maintenance and other intellectual property issues; any future changes in management or loss of key personnel; unforeseen problems associated with international revenue and operations, including gains and losses from foreign currency exchange; product liability lawsuits brought against us or our customers; implementation of or changes in laws, regulations or policies that could negatively affect the orthopedic device market; and other uncertainties and factors discussed in the “Risk Factors” section of the Corporation’s Annual Report on Form 10-K filed on March 13, 2007, elsewhere in this Quarterly Report on Form 10-Q and in the Corporation’s other filings with the Securities and Exchange Commission.

Forward-looking statements relate only to events as of the date on which the statements are made. Except as required by law, the Corporation’s undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, even if new information becomes available in the future.

14

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

For financial market risks related to changes in interest rates, foreign currency exchange rates, commodity prices and the effects of inflation, reference is made to Item 7a “Quantitative and Qualitative Disclosures About Market Risk” contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December 30, 2006. Our exposure to these risks has not changed materially since December 30, 2006.

ITEM 4. CONTROLS AND PROCEDURES

(a)   Evaluation of disclosure controls and procedures.

Our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934), have concluded that, as of the end of the fiscal quarter covered by this report on Form 10-Q, our disclosure controls and procedures were adequate and designed to ensure that material information relating to the Corporation and its consolidated subsidiaries would be made known to them by others within those entities.

(b)  Changes in internal control over financial reporting.

During the quarter, there have been no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) that occurred during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except that we are still in the process of integrating the Riley Medical, Everest Metal and Clamonta Ltd. operations and will be incorporating these operations as part of our internal controls. For purposes of this evaluation, the impact of these acquisitions on our internal controls over financial reporting has been excluded. See Note 10 to the condensed consolidated financial statements included in Item 1 for a discussion of the Clamonta Ltd acquisition.

PART II OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

None.

ITEM 1A RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2006, which could materially affect our business, financial condition or future results. The Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2006 have not materially changed.

ITEM 2 UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 5 OTHER INFORMATION

(b)There have been no material changes to the procedures by which security holders may recommend nominees to our Board of Directors since our Schedule 14A filed March 21, 2006.

ITEM 6 EXHIBITS

10.28	Stock Purchase Agreement, dated April 2, 2007, between Symmetry Medical USA Inc. and Roger M. Burke (incorporated by reference to Exhibit 10.1 from our Form 8-K, filed April 5, 2007).
10.29	Separation Letter, dated April 12, 2007, between Andrew J. Miclot and Symmetry Medical Inc.
31.1	Certification of Chief Executive Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

15

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SYMMETRY MEDICAL INC.
By	/s/ BRIAN MOORE
	Brian Moore,
	President and Chief Executive Officer
	(Principal Executive Officer)
By	/s/ FRED HITE
	Fred Hite,
	Senior Vice President and Chief Financial Officer
	(Principal Financial and Accounting Officer)

May 9, 2007

16

EX-10.29

EXHIBIT 10.29

April 12, 2007
Andrew Miclot
1625 S Meadow Dr.
Warsaw, IN 46580

Dear Andy:

This letter will confirm the Agreement between you and Symmetry Medical Inc. (the “Company”) as follows:

1)Separation from the Company: By signing this agreement you acknowledge that your separation from the Company is effective April 12, 2007 (the “Separation Date”). As of the Separation Date, you are no longer required to fulfill any of the duties and responsibilities associated with your positions at the Company and its subsidiaries. By April 30th, 2007, the Company agrees to make a lump sum payment to you in the amount of thirteen weeks of your base pay, so long as you do not revoke this agreement as provided for below.

2)Membership: After December 31, 2007 the Company will no longer pay for your Country Club Membership.

3)Company Car: You may keep your company car for six months following the Separation Date or until you become employed by another company that provides you with a company car, whichever occurs first. At that time you can turn it in to the Company or take over the lease. You may keep your cell phone number, e-mail address, blackberry and laptop until May 2, 2007.

4)Stock:

a.Restricted Stock: You currently own 12,000 shares of performance based restricted stock which you have been awarded, pursuant to certain Restricted Stock Agreements, dated as of May 16, 2005 and July 7, 2006 between you and the Company (the “Restricted Stock Agreements”), of which zero shares are currently vested. These shares have a performance based vesting schedule with cliff vesting at the end of December 2008. The Company agrees that you may keep the Restricted Stock for the life of the restricted stock per the Restricted Stock Agreement and that the board has waived clause #5 relating to forfeiting the shares if you are no longer an employee in either consideration for the terms described in 7, 8) c. and 9) below.

b.Options. You currently own 6,517 stock options to that certain Stock Option Agreement, date as of July 29, 2003 between you and the Company (the “Stock Option Agreement”), of which 100% of the shares are currently vested. The Company agrees that you may keep these vested Options for the life of the Options and that the Board of Directors has waived clause #5 (a) relating to forfeiting or selling the shares within 30 days of your departure in consideration for the terms described in 7, 8(c) and 9 below.

5)Out-Placement: The Company offers out-placement services.

6)Benefits: Beginning on the Separation Date, you will be eligible to participate under the Company’s medical plan for eighteen months pursuant to COBRA and the Company will be responsible for all costs associated with such coverage through October 2, 2008. After which time if you choose to

200 West Market Street · Warsaw, IN 46580, USA ·T:+1.574.268.2252 ·F:+1.574.267.4551

·www.symmetrymedical.com

Continue with COBRA you will be responsible for all costs of coverage. In the event that you become employed by another company that provides benefits your COBRA coverage will end.

7)Release by You:

a.You (for self, your heirs, assigns or executors) release and forever discharge the Company, any of its affiliates, and its directors, officers, agents and employees from any and all claims, suits demands, causes of action, contracts, covenants obligations, debts, costs, expenses, attorney’s fees, liabilities of whatever kind or nature in law or equity, by statue or otherwise whether now known or unknown, vested or contingent, suspected or unsuspected, and whether or not concealed or hidden, which have existed or may have existed, or which do exist, through the date this letter agreement becomes effective and enforceable (“Claims”) of any kind, which relate in any way to your employment with the Company or the termination of that employment except those arising out of the performance of this letter agreement. Such released claims include, without in any way limiting the generality of the foregoing language, any and all claims of employment discrimination under any local, state or federal law or ordinance, including without limitation, Title VII or the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; the Americans with Disabilities Act of 1990l and the Age Discrimination in Employment Act of 1967, as amended. You further acknowledge that except as set forth in this letter agreement, you are not entitled to any other salary, bonus, severance, reimbursement of any kind, benefit or expectation of remuneration or other monies from the Company or any of its affiliates.

b.In signing this Release you acknowledge that you intend that it shall be effective as a bar to each and every one of the Claims hereinabove mentioned or implied. You expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown unsuspected Claims (notwithstanding any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims hereinabove mentioned or implied. You acknowledge and agree that this waiver the Company would not make the Severance Payments described in paragraph one and four. You further agree that in the event you seek to recover against the Company in any Claim brought by a governmental agency on your behalf, this release shall serve as a complete defense to such Claims.

c.By signing this letter agreement, you acknowledge that you:

i.have been given thirty days after receipt of this letter agreement within which to consider it;

ii.have carefully read and fully understand all of the provisions of this letter agreement;

iii.knowingly and voluntarily agree to all of the terms set forth in this agreement;

iv.knowingly and voluntarily agree to be legally bound by this letter agreement;

v.have been advised and encouraged in writing (via this agreement) to consult with an attorney prior to signing this letter agreement;

vi.understand that this letter agreement, including the Release, shall not become effective and enforceable until the eighth day following execution of this letter agreement, and that at any time prior to the effective day you can revoke this letter agreement;

vii.understand you may revoke this Letter Agreement within seven (7) days by providing written notice to Anthony M. Stites, 215 East Berry Street, Fort Wayne, Indiana 46802.

8)Additional Agreement:

a.You also agree not to disparage the Company, or its past and present investors, directors, officers, other affiliates or employees, and to keep all confidential and propriety information about the past and present business affairs of the Company confidential unless a prior written release from the Company is obtained.

b.You further agree that as of the date hereof, you have returned to the Company any and all property, tangible or intangible, relating to its business, which you possessed or had control over at any time, including but not limited to company provided credit cards, building or office access cards, keys, computer equipment, manuals, files, documents, records, software, customer data base and other data that you shall not retain any copies, compilations, extracts, excerpts, summaries or other notes of any such manual files, documents, records, software, customer data base or other. This does not include any exceptions stated in this letter to the above.

c.You also agree for the period from April 11, 2007 until December 31, 2008, that you will serve as a consultant to the Company and to make yourself available as requested and necessary to a reasonable amount of questions from the Company related to your prior position and/or questions about the orthopedic industry. You agree to this until December 31, 2008 to consult on matters related to your prior position, the Company or the orthopedic industry.

9)Confidential Information: You agree to keep confidential all confidential information and trade secrets of the Company and to refrain from disclosing any confidential information and/or trade secrets without written permission of the President and CEO of the Company.

10)Non-compete: In further consideration to the amount to be paid to you hereunder, you hereby agree until December 31, 2008 to not engage directly or indirectly in the same or substantially similar business in which the Company or any of its affiliates engages as of the Separation Date anywhere within the markets in which the Company or its affiliates operates. However, that ownership of less than 5% of the outstanding stock of any publicly traded corporation shall not be deemed to be engaging solely be reason thereof in any of its businesses. Further, not withstanding the language of this section, you may accept employment with a customer or potential customer of the Company. The Company shall have the right and remedy to have the provision of paragraph 8 specifically enforced, including by temporary and/or permanent injunction, it being acknowledged and agreed that any such violation may cause irreparable injury to the Company and that money damages will not provide an adequate remedy to the Company. If any of the covenants contained in paragraph 8 is held to be unenforceable because of the duration of such provision or the area covered thereby, the parties agree that the court making such determination shall have the authority to reduce the duration and/or area of such provision and in its reduced form said provision shall then be enforceable. The length of this non-competition period shall be extended day for day for any time period that you are in violation of any of these restrictions.

11)Confidentiality of the Letter Agreement: The contents of this letter agreement, including but not limited to its financial terms, are strictly confidential. By signing this agreement you agree and represent that you will maintain the confidential nature of the agreement, except (a) to legal counsel, tax and financial planners, and immediate family who agree to keep it confidential; (b) as otherwise required by law, in which case you shall notify the Company in writing in advance of the disclosure; and (c) as necessary to enforce this letter agreement.  The Company agrees that it will keep the contents of this letter agreement confidential, except (a) to its executive staff and governing bodies, as necessary or appropriate, and its outside counsel and auditors; (b) as otherwise required by law including, but not limited to, requirements of the Securities and Exchange Commission and the New York Stock Exchange; and (c) as necessary to enforce this letter agreement.

12)No Transfer or Assignment: You and the Company agree that no interest or right you have or any of your beneficiaries has to receive payment or to receive benefits under this agreement shall be subject in any manner to sale, transfers assignment, pledge, attachment, garnishment, or other alienation or encumbrance of any kind, except as required by law. Nor may such interest or right to receive payment or distribution be taken, voluntarily or involuntarily, for the satisfaction of the obligations or debts of, or other claims, against you or your beneficiary, including for alimony, except to the extent required by law.

13)No Admissions: This letter agreement shall not be construed as an admission of any wrongdoing either by the Company or, its affiliates, or its officers, agents and employees.

14)Complete Agreement Amendment: This letter agreement contains the entire agreement between you and the Company with respect to the terms of your separation from the Company and its subsidiaries. No part of this letter agreement may be amended or modified except in writing, executed by both you and the Company.

15)Governing Law: This letter agreement shall be interpreted in accordance with the laws of the State of Indiana. Whenever possible each provision of this letter agreement shall be interpreted in a manner as to be effective and valid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or affecting the remainder of such provision or any of the remaining provisions of this letter agreement.

16)Counterparts. This letter agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.

17)Further Assurance: You hereby agree to execute, acknowledge and deliver to the Company any further documents reasonable requested by the Company to effectuate your separation from the Company and each of its subsidiaries as an officer, director, or otherwise.

Please indicate your agreement by signing this letter and returning it to me.

	Very truly yours,
	By:	/s/ Brian S. Moore
		Brian S. Moore
		CEO Symmetry Medical Inc.
AGREED AND ACCEPTED
The 12th of April, 2007
/s/ Andrew J. Miclot
Andrew J. Miclot

200 West Market Street · Warsaw, IN 46580, USA ·T:+1.574.268.2252 ·F:+1.574.267.4551

·www.symmetrymedical.com

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Brian Moore, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Symmetry Medical Inc. (the “Corporation”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Corporation as of, and for, the periods presented in this report;

4.The Corporation’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e)and 15d-15(e)) for the Corporation and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Corporation, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the Corporation’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the Corporation’s internal control over financial reporting that occurred during the Corporation’s most recent fiscal quarter (the Corporation’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Corporation’s internal control over financial reporting; and

5.The Corporation’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Corporation’s auditors and the audit committee of the Corporation’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Corporation’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Corporation’s internal controls over financial reporting.

May 9, 2007

/s/ BRIAN MOORE

Brian Moore

Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Fred Hite, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Symmetry Medical Inc. (the “Corporation”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Corporation as of, and for, the periods presented in this report;

4.The Corporation’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e)and 15d-15(e)) for the Corporation and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Corporation, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the Corporation’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the Corporation’s internal control over financial reporting that occurred during the Corporation’s most recent fiscal quarter (the Corporation’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Corporation’s internal control over financial reporting; and

5.The Corporation’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Corporation’s auditors and the audit committee of the Corporation’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Corporation’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Corporation’s internal controls over financial reporting.

May 9, 2007

/s/ FRED HITE

Fred Hite

Chief Financial Officer

EX-32.1

EXHIBIT 32.1

Section 1350 Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Symmetry Medical Inc., a Delaware corporation (the “Corporation”), does hereby certify that:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 (the “Form 10-Q”) of the Corporation fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Corporation.

May 9, 2007

/s/ BRIAN MOORE

Brian Moore

Chief Executive Officer

/s/ FRED HITE

Fred Hite

Chief Financial Officer